Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that low-dose IL-2 and IL-15 may help restore immune tolerance in alopecia areata by maintaining Treg cell function, presenting a potential new treatment strategy.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This study concluded that patients with alopecia areata receiving Janus kinase inhibitors are not maintaining the recommended frequency of lab monitoring every three months, indicating a need for new strategies to improve adherence.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

This research explored the use of machine learning and deep learning methods to accurately identify alopecia areata in humans by analyzing facial images and demonstrated the potential of these techniques for medical, security, and commercial applications.

This narrative review found that while AI-based tools in dermatology, particularly for hair disorder assessment, have potential to enhance clinical practice by improving objectivity and personalization, they currently serve mainly a complementary role and face challenges like methodological limitations and data bias.

This study presents a new classification of adult human scalp hair patterns based on high-resolution photographs, which may assist hair restoration surgeons and dermatologists in determining appropriate punch size for follicular unit extraction.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

This article discusses advancements and methodologies in epitope identification for autoimmune diseases, specifically alopecia areata, but does not report new experimental results.

In this study using diabetic rat models, the combination of AMD3100 and low-dose FK506 reduced wound healing time and improved microcirculation in diabetic foot ulcers, indicating a promising new systemic therapy.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.

This study found that hyperpigmentation following contact immunotherapy for severe alopecia areata may indicate poor treatment responsiveness and aligns with characteristics of pigmented contact dermatitis.

Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This research found that prolonged doses of Amlodipine at 5mg/kg BW or higher impaired fertility indicators in adult male rats, affecting sperm morphology, count, and motility.

This study found that extracts from the rice variety Bue Bang 3 CMU, particularly the husk and bran, demonstrated antioxidant, anti-inflammatory, and anti-androgenic properties, suggesting potential use in treating androgenetic alopecia.

This study found that men with adrenomyeloneuropathy often experience diffuse hair loss and severe male-pattern baldness, potentially due to the X-linked ALD mutation's role in androgenetic alopecia's genetic spectrum.

This study found that Hataedock may alleviate atopic dermatitis symptoms in mice by maintaining skin homeostasis and improving skin barrier formation through the endocannabinoid system.

This study reviewed literature and assessed clinical data on treating alopecia areata linked with atopic diseases, finding that therapies like dupilumab, phototherapy, and JAK inhibitors may address overlapping symptoms, suggesting a focus on reducing pharmacological burden and enhancing quality of life.

This study revealed that in androgenic alopecia, the proximal attachment of the arrector pili muscle to the hair follicle is often lost or significantly reduced.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.